Skip to content
Sulfaphenazole
Sulfabid (sulfaphenazole) is a small molecule pharmaceutical. Sulfaphenazole was first approved as Sulfabid on 1982-01-01. It is known to target cytochrome P450 2C9.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfaphenazole
Tradename
Company
Number
Date
Products
SULFABIDPharmaceutical Research Associates IncN-013093 DISCN1982-01-01
1 products
SULFABIDPurdue PharmaN-013092 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01E: Sulfonamides and trimethoprim antibacterials for systemic use
— J01ED: Long-acting sulfonamides
— J01ED08: Sulfaphenazole
HCPCS
No data
Clinical
Clinical Trials
154 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2036144530
Pneumocystis pneumoniaD011020EFO_0007448B5914122219
Urinary tract infectionsD014552EFO_0003103N39.0—355215
InfectionsD007239EFO_0000544122318
MalariaD008288EFO_0001068B54——71—8
PneumoniaD011014EFO_0003106J18—141—5
Methicillin-resistant staphylococcus aureusD055624—211—4
TuberculosisD014376EFO_0000774A15-A19—221—4
HivD006678O98.7——12—3
BacteriuriaD001437R82.7111—1—3
Show 23 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A49311—16
AbscessD000038EFO_0003030——2—46
SepsisD018805A41.9—13——4
Staphylococcal infectionsD013203A49.01—23——4
MycosesD009181B35-B491—1——2
PneumocystisD011010——2——2
Idiopathic pulmonary fibrosisD054990J84.112——2——2
Multiple myelomaD009101C90.0—11——2
Vesico-ureteral refluxD014718EFO_0007536N13.7——2——2
OsteomyelitisD010019EFO_0003102M86——1—12
Show 16 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.913——14
Cystic fibrosisD003550EFO_0000390E84—3———3
SinusitisD012852EFO_0007486J32—1——12
Type 1 diabetes mellitusD003922EFO_0001359E10—1——12
Chronic kidney failureD007676EFO_0003884N18.6—1——12
NeoplasmsD009369C8021———2
Staphylococcus aureusD013211NCBITaxon_1280—1——12
LeukemiaD007938C9512———2
Kidney diseasesD007674EFO_0003086N0822———2
Kidney transplantationD01603022———2
Show 19 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Congenital microtiaD065817Q16.01————1
Short bowel syndromeD0127781————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BronchitisD001991J40————33
HypospadiasD007021EFO_0004209Q54————22
DeliriumD003693R41.0————11
Ulcerative colitisD003093EFO_0000729K51————11
Non-hodgkin lymphomaD008228C85.9————11
Pregnancy complicationsD011248————11
UrolithiasisD052878N20-N23————11
Bacterial skin diseasesD017192————11
CellulitisD002481EFO_0003035L03.90————11
Diabetic footD017719EFO_1001459————11
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULFAPHENAZOLE
INNsulfaphenazole
Description
Sulfaphenazole is a sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent. It has a role as an antibacterial drug, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor and a P450 inhibitor. It is a substituted aniline, a sulfonamide, a member of pyrazoles, a primary amino compound and a sulfonamide antibiotic.
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
Identifiers
PDB—
CAS-ID526-08-9
RxCUI—
ChEMBL IDCHEMBL1109
ChEBI ID77780
PubChem CID5335
DrugBankDB06729
UNII ID0J8L4V3F81 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CYP2C9
CYP2C9
Organism
Homo sapiens
Gene name
CYP2C9
Gene synonyms
CYP2C10
NCBI Gene ID
1559
Protein name
cytochrome P450 2C9
Protein synonyms
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, Cholesterol 25-hydroxylase, CYPIIC9, cytochrome P-450 S-mephenytoin 4-hydroxylase, Cytochrome P-450MP, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, cytochrome P450, family 2, subfamily C, polypeptide 9, flavoprotein-linked monooxygenase, microsomal monooxygenase, S-mephenytoin 4-hydroxylase, xenobiotic monooxygenase
Uniprot ID
Q8WW80
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 787 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
33,192 adverse events reported
View more details